129 related articles for article (PubMed ID: 22430209)
1. PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs.
Ross RL; Askham JM; Knowles MA
Oncogene; 2013 Feb; 32(6):768-76. PubMed ID: 22430209
[TBL] [Abstract][Full Text] [Related]
2. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
3. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
4. Functional analysis of PIK3CA gene mutations in human colorectal cancer.
Ikenoue T; Kanai F; Hikiba Y; Obata T; Tanaka Y; Imamura J; Ohta M; Jazag A; Guleng B; Tateishi K; Asaoka Y; Matsumura M; Kawabe T; Omata M
Cancer Res; 2005 Jun; 65(11):4562-7. PubMed ID: 15930273
[TBL] [Abstract][Full Text] [Related]
5. PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma.
Ross RL; McPherson HR; Kettlewell L; Shnyder SD; Hurst CD; Alder O; Knowles MA
BMC Cancer; 2016 Jul; 16():553. PubMed ID: 27465249
[TBL] [Abstract][Full Text] [Related]
6. Activation of the PI3K/AKT signalling pathway in non-melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations.
Hafner C; Landthaler M; Vogt T
Exp Dermatol; 2010 Aug; 19(8):e222-7. PubMed ID: 20557351
[TBL] [Abstract][Full Text] [Related]
7. Re: PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs.
Atala A
J Urol; 2013 Sep; 190(3):1131. PubMed ID: 23931235
[No Abstract] [Full Text] [Related]
8. Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner.
di Martino E; L'Hôte CG; Kennedy W; Tomlinson DC; Knowles MA
Oncogene; 2009 Dec; 28(48):4306-16. PubMed ID: 19749790
[TBL] [Abstract][Full Text] [Related]
9. PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models.
Nisa L; Häfliger P; Poliaková M; Giger R; Francica P; Aebersold DM; Charles RP; Zimmer Y; Medová M
Mol Cancer; 2017 May; 16(1):93. PubMed ID: 28532501
[TBL] [Abstract][Full Text] [Related]
10. Mutation-Associated Phenotypic Heterogeneity in Novel and Canonical PIK3CA Helical and Kinase Domain Mutants.
Ghodsinia AA; Lego JMT; Garcia RL
Cells; 2020 Apr; 9(5):. PubMed ID: 32365913
[TBL] [Abstract][Full Text] [Related]
11. Integrated genomic and transcriptional analysis of the in vitro evolution of telomerase-immortalized urothelial cells (TERT-NHUC).
Chapman EJ; Williams SV; Platt FM; Hurst CD; Chambers P; Roberts P; Knowles MA
Genes Chromosomes Cancer; 2009 Aug; 48(8):694-710. PubMed ID: 19405089
[TBL] [Abstract][Full Text] [Related]
12. Urothelium-Specific Expression of Mutationally Activated Pik3ca Initiates Early Lesions of Noninvasive Bladder Cancer.
Shuman L; Pham J; Wildermuth T; Wu XR; Walter V; Warrick JI; DeGraff DJ
Am J Pathol; 2023 Dec; 193(12):2133-2143. PubMed ID: 37544503
[TBL] [Abstract][Full Text] [Related]
13. Activated mutant forms of PIK3CA cooperate with RasV12 or c-Met to induce liver tumour formation in mice via AKT2/mTORC1 cascade.
Wang C; Che L; Hu J; Zhang S; Jiang L; Latte G; Demartis MI; Tao J; Gui B; Pilo MG; Ribback S; Dombrowski F; Evert M; Calvisi DF; Chen X
Liver Int; 2016 Aug; 36(8):1176-86. PubMed ID: 26716908
[TBL] [Abstract][Full Text] [Related]
14. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.
Kang S; Bader AG; Vogt PK
Proc Natl Acad Sci U S A; 2005 Jan; 102(3):802-7. PubMed ID: 15647370
[TBL] [Abstract][Full Text] [Related]
15. Hotspot mutations of PIK3CA and AKT1 genes are absent in multiple myeloma.
Ismail SI; Mahmoud IS; Msallam MM; Sughayer MA
Leuk Res; 2010 Jun; 34(6):824-6. PubMed ID: 20022634
[TBL] [Abstract][Full Text] [Related]
16. In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA.
Kong D; Yamori T; Yamazaki K; Dan S
Invest New Drugs; 2014 Dec; 32(6):1134-43. PubMed ID: 25152245
[TBL] [Abstract][Full Text] [Related]
17. PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors.
Dueñas M; Martínez-Fernández M; García-Escudero R; Villacampa F; Marqués M; Saiz-Ladera C; Duarte J; Martínez V; Gómez MJ; Martín ML; Fernández M; Castellano D; Real FX; Rodriguez-Peralto JL; De La Rosa F; Paramio JM
Mol Carcinog; 2015 Jul; 54(7):566-76. PubMed ID: 24347284
[TBL] [Abstract][Full Text] [Related]
18. Mutation of the PIK3CA gene in anaplastic thyroid cancer.
García-Rostán G; Costa AM; Pereira-Castro I; Salvatore G; Hernandez R; Hermsem MJ; Herrero A; Fusco A; Cameselle-Teijeiro J; Santoro M
Cancer Res; 2005 Nov; 65(22):10199-207. PubMed ID: 16288007
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas.
Murugan AK; Hong NT; Fukui Y; Munirajan AK; Tsuchida N
Int J Oncol; 2008 Jan; 32(1):101-11. PubMed ID: 18097548
[TBL] [Abstract][Full Text] [Related]
20. Cancer-specific mutations in PIK3CA are oncogenic in vivo.
Bader AG; Kang S; Vogt PK
Proc Natl Acad Sci U S A; 2006 Jan; 103(5):1475-9. PubMed ID: 16432179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
